Planting Hope for a Greener Tomorrow: World Environment Day Event at Manipal Hospital Malleshwaram Rooted for Environmental Awareness & Action
The event was graced by Mr. N. Ravindrakumar, Deputy Conservator of Forests, Bengaluru Urban Division, as the Chief Guest, and Mr. Abdul Hafeez , Hospital Director, Manipal Hospital Malleshwaram, who joined hands with students, neighbourhood residents, and hospital staff to plant saplings and share the message of environmental sustainability. The event was also attended by eminent health experts, including Dr. G. K. Prakash, Consultant – Nephrology, and Transplant Physician, Dr. Vikas G. K., Consultant – Emergency Medicine, and Dr. Puneeth B. S., Consultant – Medical Gastroenterology, who aimed to bring sustainable change for a greener tomorrow.
The day began with a plantation drive at Jagadguru Sri Adi Shankaracharya Udyanavana, a BBMP park maintained by the hospital. Students from Hymamshu Jyothi Kala Peetha School and Cluny Convent High School, accompanied by their teachers, along with the chief guest, community members, consultants, and senior citizens, took part in the activity.
As part of a learning experience, a guided tour of the park was organized, where students could explore posters that explained the ecological significance of various trees. This was followed by engaging activities such as an Essay Competition on the theme 'Ending Plastic Pollution Globally' and Handprint Tree Board as a pledge towards protecting the environment.
A special highlight of the event involved students getting a closer look inside the MARS Ambulance (Manipal Ambulance Response Service), learning about its services, and how it connects to community well-being during emergencies.
Mr. N. Ravindrakumar, Deputy Conservator of Forests, Bengaluru Urban Division, stated, 'On this World Environment Day, it's encouraging for the hospital to invite students to participate in the sapling plantation drive. Children are the future stewards of our planet, and it is crucial to instill in them a sense of responsibility towards environmental conservation. Educating them about the impact of environmental pollution, like air and water contamination, is equally important. Initiatives like this plantation drive serve as powerful, experiences that nurture awareness and action in the young minds of tomorrow.'
Ms Rajani, Subject Teacher, Hymamshu Jyothi Kala Peetha School, said, 'Today, as we have gathered to attend the World Environment Day celebration by Manipal Hospital Malleshwaram, I would like to thank the team for the opportunity offered to our students. It's such an amazing program to participate and create awareness to protect our environment. We should definitely inculcate these good habits to save our surroundings and work towards a better and greener future.'
Ms. Chetana, Computer Science Teacher, Cluny Convent High School, noted, 'We were delighted to take part in the sapling plantation drive. The students also enthusiastically participated in the essay writing and quiz competitions. I had always associated Manipal Hospital primarily with patient care, but today I witnessed their admirable commitment to promoting environmental awareness and sustainability. Their initiative to engage young minds in such meaningful activities is truly commendable.'
Through this initiative, Manipal Hospital Malleshwaram inspired kids to be the Environmental Ambassadors of Tomorrow, where they gain environmental awareness to bring positive change for a greener urban ecosystem.
For more information, please visit: https://www.manipalhospitals.com/malleshwaram/
Photo: https://mma.prnewswire.com/media/2706074/Manipal_Hospital_Malleshwaram_1.jpg
Photo: https://mma.prnewswire.com/media/2706075/Manipal_Hospital_Malleshwaram_2.jpg
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Xtalks Announces its Life Science Webinar Calendar for August 2025
Upcoming free, educational webinars from Xtalks will feature topics on cell and gene therapy, clinical trials, commercialization & HEOR, drug discovery & development, healthcare, laboratory technology, medical device, patient recruitment & retention, pharma manufacturing & supply chain and preclinical. TORONTO, Aug. 1, 2025 /PRNewswire/ -- Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries. Access to all webinars is free, so be sure to register today to save your place! Participate in the discussion and stay relevant in your field! Visit to see our upcoming webinars: CELL AND GENE THERAPYAugust 22 - How Cell-Free mRNA Templates Support Faster Research with High-Quality and Quick Turnaround CLINICAL TRIALSAugust 7 - Improving Clinical Tech Adoption: Site-Centric ApproachesAugust 13 - Accelerating Clinical Research with Master Protocols: Challenges and Benefits to Complex Trial DesignsAugust 14 - Designing Innovative Trials: Navigating Dose Optimization in Oncology CombinationsAugust 15 - AI in Clinical Trials: Early Use Cases and Innovations COMMERCIALIZATION & HEORAugust 19 - 5 Critical Questions to Ask Before Applying AI to Real-World Data DRUG DISCOVERY & DEVELOPMENTAugust 7 - Oral Dosage Innovation for Pediatric Drug DeliveryAugust 7 - Cancer Drug Discovery: A Synthetic Lethality Approach Using Integrated PlatformsAugust 12 - Radiotracers and ADC Targeting: Scientific Insights for In Vivo Validation and Clinical TransitionAugust 13 - AI in Drug Discovery & Development: Hype, Reality and What Comes NextAugust 21 - Dose Escalation: Optimizing Cohort Management in Early-Phase DevelopmentAugust 26 - AI in Bioprocessing Today — Accelerate. Predict. Deliver. HEALTHCAREAugust 20 - Beyond Diagnosis: The Real-World Impact of AVISE Testing on Lupus, Rheumatoid Arthritis, and Autoimmune Disease Care LABORATORY TECHNOLOGYAugust 6 - Precision Matters: The Critical Role of Accurate Liquid Handling in the Lab MEDICAL DEVICEAugust 25 - Transforming Medical Imaging with AI: Open Tools, Faster Insights PATIENT RECRUITMENT & RETENTIONAugust 20 - Transforming Patient Recruitment: AI and Digital Strategies to Engage the Unreachable 95%August 27 - Enhancing Patient Recruitment in Clinical Research: A Personalized and Engaged Journey PHARMA MANUFACTURING & SUPPLY CHAINAugust 14 - Biofermentation Success Through pH and DO Management PRECLINICALAugust 26 - Advanced In Vivo Efficacy Models for Preclinical Success ABOUT XTALKS Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers. To learn more about Xtalks visit Contact:Ayesha RashidXtalks ( Tel: +1 (416) 977-6555 x371Email: arashid@ View original content to download multimedia: SOURCE Xtalks Inicia sesión para acceder a tu cartera de valores
Yahoo
2 days ago
- Yahoo
OSR Holdings to Host Virtual Investor Event Providing Key Corporate Updates and Strategic Direction on August 6, 2025
BELLEVUE, Wash., Aug. 1, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical innovations to improve health and wellness worldwide, today announced that it will host a Virtual Investor Event on Wednesday, August 6, 2025 at 8:00 a.m. Eastern Time (2:00 p.m. Central European Summer Time / 9:00 p.m. Korea Standard Time). The event will provide shareholders and prospective investors with a detailed update of the Company's strategic direction, subsidiary performance, capital allocation, and pipeline R&D. Senior members of the OSRH executive team will be presenting. Event Details Date: Wednesday, August 6, 2025Time: 8:00 a.m. ET / 2:00 p.m. CEST / 9:00 p.m. KSTLocation: Virtual (livestream access)Registration: Opens Monday, August 4 at Available after the event on the OSR Holdings Investor Relations website. Agenda Highlights Corporate overview and strategic vision Subsidiary and R&D pipeline updates: Vaximm: Tailored, Antigen-specific in vivo T-cell Immunotherapies Darnatein: DRT101 – a potent DMOAD candidate Woori IO acquisition: The opportunity for noninvasive CGM Equity Line of Credit (ELOC) financing strategy Blockchain & Tokenization strategy Live Q&A with management "This event is a timely opportunity to engage with our shareholders and the broader investment community as we move into a transformative stage in OSR's growth," said Peter Hwang, CEO of OSRH. "We look forward to showcasing the strength of our platform, the progress we've made, and the catalysts ahead. We are committed to transparency, disciplined execution, and delivering meaningful value to all stakeholders in the coming months."Featured Speakers: Mr. Peter Hwang – Chief Executive Officer Dr. Constance Höfer – Chief Scientific Officer Mr. Tim Smith – Global Investor Relations About OSR Holdings, Inc. OSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company dedicated to advancing biomedical innovation approaches to health and wellness to support global health outcomes. Through its subsidiaries, OSRH is engaged in immuno‑oncology, regenerative biologics, and medical device distribution. OSRH's vision is to acquire and operate a portfolio of innovative healthcare and wellness companies, improving patient care through cutting‑edge research and development. For more information, visit View original content to download multimedia: SOURCE OSR Holdings Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
2 days ago
- Yahoo
Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference
Presentations to include efficacy, safety and opioid use reduction data in two different surgery models as well as pharmacokinetics data PITTSBURGH, Aug. 1, 2025 /PRNewswire/ -- Viatris (Nasdaq: VTRS), a global healthcare company, today announced that five abstracts from its Phase 3 program evaluating novel fast-acting formulation of meloxicam (MR-107A-02) in moderate-to-severe acute surgical pain models will be presented at the PAINWeek 2025 national conference in Las Vegas from September 2-5, 2025. The presentations will include positive results from two previously announced pivotal studies in herniorrhaphy (NCT06215859) and bunionectomy (NCT06215820) surgery models. All accepted scientific abstracts are now available on the PAINWeek website. Full List of Viatris Presentations at PAINWeek 2025 Poster Title Presentation Details Poster #41 Pharmacokinetics study comparing MR-107A-02 (novel fast-acting meloxicam formulation) 15mg tablet with meloxicam (Mobic®) 15mg in healthy adult male subjects. Live Abstract Presentation Thursday, Sept. 4 4:35 p.m. - 4:45 p.m. PDT Poster #39 Efficacy and safety of MR-107A-02 (novel fast-acting meloxicam formulation) for the treatment of acute moderate-to-severe pain following bunionectomy Live Abstract Presentation Thursday, Sept. 4 4:50 p.m. - 5:00 p.m. PDT Poster #38 Efficacy and safety of MR-107A-02 (novel meloxicam fast-acting formulation) for the treatment of acute moderate-to-severe pain following herniorrhaphy. Live Abstract Presentation Thursday, Sept. 4 5:05 p.m. - 5:15 p.m. PDT Poster #40 Opioid sparing effect of MR-107A-02 (novel fast-acting meloxicam formulation) for the treatment of acute moderate-to-severe pain following bunionectomy and herniorrhaphy. Live Abstract Presentation Thursday, Sept. 4 5:20 p.m. - 5:30 p.m. PDT Poster #76 Efficacy and Safety of a Rapid-Absorption Formulation of Meloxicam in the Treatment of Acute Postoperative Pain Following Bunionectomy and Herniorrhaphy Poster presentation only About Viatris Viatris (Nasdaq: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at and and connect with us on LinkedIn, Instagram, YouTube and X. Forward-Looking StatementsThis press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include statements that about the results of clinical trials. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the uncertainties inherent in research and development, including the outcomes of clinical trials; the ability to meet anticipated clinical endpoints; the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from clinical studies; actions and decisions of healthcare and pharmaceutical regulators; our ability to comply with applicable laws and regulations; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any regulatory, legal or other impediments to Viatris' ability to bring new products to market; products in development and/or that receive regulatory approval may not achieve expected levels of market acceptance, efficacy or safety; longer review, response and approval times as a result of evolving regulatory priorities and reductions in personnel at health agencies; Viatris' or its partners' ability to develop, manufacture, and commercialize products; the scope, timing and outcome of any ongoing legal proceedings, and the impact of any such proceedings on Viatris; Viatris' failure to achieve expected or targeted future financial and operating performance and results; goodwill or impairment charges or other losses; any changes in or difficulties with the Company's manufacturing facilities; risks associated with international operations; changes in third-party relationships; the effect of any changes in Viatris' or its partners' customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of Viatris or its partners; uncertainties regarding future demand, pricing and reimbursement for the Company's products; uncertainties and matters beyond the control of management, including but not limited to general political and economic conditions, potential adverse impacts from future tariffs and trade restrictions, inflation rates and global exchange rates; and the other risks described in Viatris' filings with the Securities and Exchange Commission ("SEC"). Viatris routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no obligation to update these statements for revisions or changes after the date of this press release other than as required by law. View original content to download multimedia: SOURCE Viatris Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
